Summary

Medical monotherapy by functional class (NYHA) (currently available in Switzerland)
Recommendation,
evidence
Class II Class III Class IV
I, A Ambrisentan
Bosentan
Sildenafil
Ambrisentan
Bosentan
Sildenafil
IV Epoprostenol
IV Epoprostenol
I, B Macitentan
Tadalafil
Riociguat
Selexipag
SC Treprostinit
Macitentan
Tadalafil
Riociguat
Inhaled Iloprost
Treprostinil
Selexipag
 
Ila, C   IV Iloprost
IV Treprostinil
 
Ilb, C     Ambrisentan
Bosentan
Macitentan
Sildenafil
Tadalafil
Riociguat
Inhaled Iloprost
IV Iloprost
SC Treprostinil
IV Treprostinil

Initial drug combination therapy by functional class (NYHA) (currently available in Switzerland)
Recommendation,
evidence
Class II Class III Class IV
I, A      
I, B

Ambrisentan +
tadalafild

Ambrisentan +
tadalafild
 
Ila, C

Other ERA +
PDE-5i

Other ERA
PDE-5i


Bosentan +
sildenafil +
i.v. epoprostenol


Bosentan + i.v.
epoprostenol


Bosentan +
sildenafil +
i.v. epoprostenol


Bosentan + i.v.
epoprostenol

Ilb, C  

Other ERA or
PDE-5i +
s.c. treprostinil

Other ERA or
PDE-5i + other
i.v. prostacyclin
analogues

Ambrisentan +
tadalafild


Other ERA+
PDE-5i

 

Other ERA or
PDE-5i +
s.c. treprostinil

Other ERA or
PDE-5i + other
i.v. prostacyclin
analogues